Ipamorelin is often discussed online, but it does not have an approved drug label from any regulatory agency. This overview covers only what is publicly registered about its research history.
Key takeaways
- Ipamorelin is classified as an unapproved research compound with no approved label.
- Three clinical trials involving ipamorelin have been registered.
- Two completed trials examined gastrointestinal recovery and post-operative ileus management.
- A third study is listed as active but not recruiting.
What ipamorelin is
Ipamorelin is a compound that has been studied in clinical research settings but has not received approval from a regulatory agency. No approved label, indication, or manufacturer-provided mechanism description is available for it.
Trial footprint
A total of three clinical trials involving ipamorelin have been registered. Two of these were phase 2 studies and have been completed. One trial, titled "Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function," examined its effects on gastrointestinal recovery. A second, "Safety and Efficacy of Ipamorelin for Management of Post-Operative Ileus," looked at post-operative ileus management. A third registered study, described as a "Trifecta Research Study," is currently active but not recruiting participants.